With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

By Paul Bonanos, Associate Editor | Jul 29, 2020 | 9:22 AM GMT

With two RNA manipulation platforms united under one roof, Dutch biotech Vico will deploy its new series A round for clinical development of a program founder and Chairman Luc Dochez knows well from his time at Prosensa.

Vico Therapeutics B.V. said Wednesday it had raised €27 million